Jaswinder Gill, Karl J Crossen, Christopher Blauth, Faraz Kerendi, Saumil R Oza, Anthony R Magnano, Mark A Mostovych, Michael E Halkos, David Tschopp, Jose Osorio, Paul Tabereaux, William Boedefeld, Kenneth Civello, Syed Ahsan, John Yap, Sreedhar Billakanty, Steve Duff, Otto Costantini, Eric Espinal, Andy Kiser, Christian Shults, David Pederson, James Garrison, David M Gilligan, Michael G Link, Marcin Kowalski, Christopher Stees, Jason S Sperling, Israel Jacobowitz, Felix Yang, Yisachar J Greenberg, David B De Lurgio
BACKGROUND: CONVERGE was a prospective, multicenter, randomized controlled trial that evaluated the safety of Hybrid Atrial Fibrillation Convergent (HC) and compared its effectiveness to endocardial catheter ablation (CA) for the treatment of persistent atrial fibrillation (PersAF) and longstanding PersAF (LSPAF). In 2020, we reported that CONVERGE met its primary safety and effectiveness endpoints. The primary objective of the present study is to report CONVERGE trial results for quality of life (QOL) and Class I/III anti-arrhythmic drug (AAD) utilization following HC...
March 29, 2024: Annals of Cardiothoracic Surgery